Jump to Navigation

Steve Balt, MD

Printer-friendly version

Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center

Deplin: Is it Just Folate by Another Name?

The Carlat Psychiatry Report

Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.

Nuedexta for Pseudobulbar Affect

Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.

Future Developments in Antidepressant Therapy

In 2011 in the pages of TCPR, we asked, “What’s new in antidepressant treatment?” The answer was “not much” (TCPR, April 2011). In 2012, unfortunately, the answer isn’t very different.

Does Brintellix Bring Anything New?

After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?